Atypical RAS Mutations in Metastatic Colorectal Cancer.

Abstract

PURPOSE:

To describe the clinical and molecular features of metastatic colorectal cancers (mCRCs) bearing uncommon atypical RAS (At-RAS) mutations at codons other than 12, 13, 59, 61, 117, and 146.

MATERIALS AND METHODS:

By exploiting five next-generation sequencing sources (Italian collaboration, Memorial Sloan Kettering Cancer Center, Samsung Medical Center, the Biomarker Research for Anti-EGFR Monoclonal Antibodies by Comprehensive Cancer Genomics (BREAC) study, and the Foundation Medicine database), we retrieved 175 At-RAS mutated cases. Molecular data were obtained from 163 samples from Memorial Sloan Kettering Cancer Center and the Foundation Medicine database. Clinical data were available for 27 At-RAS-positive and 467 negative cases from the Italian collaboration, Memorial Sloan Kettering Cancer Center, Samsung Medical Center, and the BREAC study.

RESULTS:

At-RAS mutations were identified in 163 (0.9%) of 18,270 mCRCs. Among 133 with evaluable microsatellite instability status, 11 (8%) were microsatellite instability high. POLE exonuclease domain mutations had higher frequency (7%) than expected and were found only in microsatellite-stable tumors with high tumor mutational burden (TMB). Overall, 17% (28 of 163) of At-RAS cases had TMB greater than 20 mutations/Mb. Co-occurring typical RAS/BRAF V600E mutations and NF1 mutations, presumed to cause RAS activation, were found in 30% and 12% of samples, respectively (up to 43% and 50%, respectively, in TMB-high samples). Patients with RAS/BRAF wild-type mCRC achieved a median overall survival (OS) of 42.1 months, whereas those harboring isolated At-RAS, typical RAS, or BRAF V600E mutations showed a median OS of 32.3, 30.0, and 17.9 months, respectively (P < .001). No significant OS difference (P = .240) was found between patients with At-RAS versus typical RAS-mutated mCRC. Only one of six patients evaluable for primary resistance to anti-epidermal growth factor receptors achieved tumor response.

CONCLUSION:

At-RAS mutations may be a marker for RAS pathway activation and can be associated with high co-occurrence of POLE exonuclease domain mutations.

• Authors: Filippo Pietrantonio, Rona Yaeger, Alexa B Schrock, Giovanni Randon, Sandra Romero-Cordoba, Daniele Rossini, Giovanni Fucà, Jeffrey S Ross, Daisuke Kotani, Russell Madison, Seung Tae Kim, Lisa Salvatore, Alessandra Raimondi, Filippo Pagani, Beatrice Borelli, Federica Perrone, Maria Di Bartolomeo, Vincent A Miller, Siraj M Ali, Jeeyun Lee, Takayuki Yoshino, Filippo de Braud, Alfredo Falcone, Jaclyn F Hechtman, Chiara Cremolini
• Journal: JCO precision oncology (JCO Precis Oncol) Vol. 3 Pg. 1-11 (Dec 2019) ISSN: 2473-4284 [Electronic] United States
• PMID: 35100719 (Publication Type: Journal Article)